<?xml version="1.0" encoding="UTF-8" standalone="no"?><?xml-stylesheet type="text/css" href="uslm.css"?><bill xmlns="http://schemas.gpo.gov/xml/uslm" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" xsi:schemaLocation="http://schemas.gpo.gov/xml/uslm https://www.govinfo.gov/schemas/xml/uslm/uslm-2.0.17.xsd">
<!--Disclaimer: Legislative measures that include compacts or other non-standard data structures will require additional modeling and may contain inconsistencies in the converted USLM XML.-->
<meta><dc:title>118 HR 8663 ENR: To require the Science and Technology Directorate in the Department of Homeland Security to develop greater capacity to detect and identify illicit substances in very low concentrations.</dc:title>
<dc:type>House Bill</dc:type><docNumber>8663</docNumber><citableAs>118 HR 8663 ENR</citableAs>
<citableAs>118hr8663enr</citableAs>
<citableAs>118 H.R. 8663 ENR</citableAs>
<dc:creator>United States House of Representatives</dc:creator><dc:publisher>United States Government Publishing Office</dc:publisher><dc:format>text/xml</dc:format><dc:language>EN</dc:language><dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights><docStage>ENR</docStage>
<processedBy>GPO Locator to USLM Converter 4.12.3;Stage2.20240826</processedBy><processedDate>2024-12-19</processedDate>
<congress>118</congress><session>2</session><publicPrivate>public</publicPrivate>
</meta>
<preface><dc:type>H. R.</dc:type><docNumber>8663</docNumber>

<congress style="-uslm-lc:I665502" value="118">One Hundred Eighteenth Congress of the United States of America</congress><session style="-uslm-lc:I665503" value="2">A T T  H  E S  E  C  O  N  D S  E  S  S  I  O  N</session>
<enrolledDateline style="-uslm-lc:I665504">Begun and held at the City of Washington on Wednesday, the third day of January, two thousand and twenty-four</enrolledDateline>
</preface>
<main>
<longTitle>
<docTitle class="centered fontsize18" style="-uslm-lc:I665505">An Act</docTitle>
<officialTitle class="centered fontsize8" style="-uslm-lc:I665511">To require the Science and Technology Directorate in the Department of Homeland Security to develop greater capacity to detect and identify illicit substances in very low concentrations.<?GPOvSpace 08?></officialTitle>
</longTitle>
<enactingFormula style="-uslm-lc:I650120"><i>  Be it enacted by the Senate and House of Representa­tives of the United States of America in Congress assembled,</i></enactingFormula>
<section id="d1542e62" identifier="/us/bill/118/hr/8663/s1" style="-uslm-lc:I650146"><num class="bold" value="1">SECTION 1. </num><heading>SHORT TITLES.</heading><content style="-uslm-lc:I650120">  This Act may be cited as the “<shortTitle role="act">Detection Equipment and Technology Evaluation to Counter the Threat of Fentanyl and Xylazine Act of 2024</shortTitle>” or the “<shortTitle role="act">DETECT Fentanyl and Xylazine Act of 2024</shortTitle>”.</content></section>
<section id="d1542e75" identifier="/us/bill/118/hr/8663/s2" role="instruction" style="-uslm-lc:I650141"><num class="fontsize12" value="2">SEC. 2. </num><heading>ENHANCING THE CAPACITY TO DETECT AND IDENTIFY DRUGS SUCH AS FENTANYL AND XYLAZINE.</heading><chapeau class="indentUp0 firstIndent0 fontsize10" id="x24207fbc-be77-11ef-bd5f-1b3d73d54f0f" style="-uslm-lc:I650120">  Section 302 of the Homeland Security Act of 2002 (<ref href="/us/usc/t6/s182">6 U.S.C. 182</ref>) <amendingAction type="amend">is amended</amendingAction>—</chapeau><paragraph class="firstIndent0 fontsize10" id="y24207fbd-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s2/1" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>in paragraph (13), by <amendingAction type="delete">striking</amendingAction> “<quotedText>and</quotedText>” at the end;</content></paragraph><paragraph class="firstIndent0 fontsize10" id="y24207fbe-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s2/2" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><content>in paragraph (14), by <amendingAction type="delete">striking</amendingAction> the period at the end and <amendingAction type="insert">inserting</amendingAction> “<quotedText>; and</quotedText>”; and</content></paragraph><paragraph class="firstIndent0 fontsize10" id="y24207fbf-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s2/3" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="3">(3) </num><content>by <amendingAction type="add">adding</amendingAction> at the end the following:<quotedContent><paragraph class="indentUp0 firstIndent0 fontsize10" id="y2420a6d0-be77-11ef-bd5f-1b3d73d54f0f" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="15">“(15) </num><chapeau>carrying out, in coordination with the Drug Enforcement Administration, research, development, testing, evaluation, and cost-benefit analyses to improve the safety, effectiveness, and efficiency of equipment and the effectiveness and efficiency of reference libraries for use by Federal, State, local, Tribal, and territorial law enforcement agencies for the accurate detection of drugs, such as fentanyl and xylazine, including—</chapeau><subparagraph class="firstIndent0 fontsize10" id="y2420a6d1-be77-11ef-bd5f-1b3d73d54f0f" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">“(A) </num><content>portable equipment that can detect and identify drugs with minimal or no handling of the sample;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y2420a6d2-be77-11ef-bd5f-1b3d73d54f0f" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">“(B) </num><content>equipment that can separate complex mixtures containing low concentrations of drugs and high concentrations of cutting agents into their component parts to enable signature extraction for field identification and detection; and</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y2420a6d3-be77-11ef-bd5f-1b3d73d54f0f" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">“(C) </num><content>technologies that use machine learning or artificial intelligence (as defined in section 5002 of the National Artificial Intelligence Initiative Act of 2020 (<ref href="/us/usc/t15/s9401">15 U.S.C. 9401</ref>)) and other techniques to predict whether the substances in a sample are controlled substance analogues or other new psychoactive substances not yet included in available reference libraries.”</content></subparagraph></paragraph></quotedContent>.</content></paragraph></section>
<section id="d1542e137" identifier="/us/bill/118/hr/8663/s3" style="-uslm-lc:I650141"><num class="fontsize12" value="3">SEC. 3. </num><heading>REQUIREMENTS.</heading><chapeau class="indentUp0 firstIndent0 fontsize10" id="x2420f4f4-be77-11ef-bd5f-1b3d73d54f0f" style="-uslm-lc:I650120">  In carrying out section 302(15) of the Homeland Security Act of 2002, as added by section 2, the Under Secretary for Science and Technology shall—</chapeau><paragraph class="firstIndent0 fontsize10" id="y2420f4f5-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s3/1" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="1">(1) </num><content>follow the recommendations, guidelines, and best practices described in the Artificial Intelligence Risk Management Framework (NIST AI 100–1) or any successor document published by the National Institute of Standards and Technology; and</content></paragraph><paragraph class="firstIndent0 fontsize10" id="y2420f4f6-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s3/2" style="-uslm-lc:I650122"><num class="fontsize10" style="-uslm-lc:emspace2" value="2">(2) </num><chapeau>establish the Directorate of Science and Technology’s research, development, testing, evaluation, and cost-benefit analysis priorities under such section 302(15) based on the latest available information, including specific drugs identified as threats in—</chapeau><subparagraph class="firstIndent0 fontsize10" id="y2420f4f7-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s3/2/A" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="A">(A) </num><content>the latest Homeland Threat Assessment published by the Department of Homeland Security;</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y2420f4f8-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s3/2/B" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="B">(B) </num><content>the latest State and Territory Report on Enduring and Emerging Threats published by the Drug Enforcement Administration; or</content></subparagraph><subparagraph class="firstIndent0 fontsize10" id="y2420f4f9-be77-11ef-bd5f-1b3d73d54f0f" identifier="/us/bill/118/hr/8663/s3/2/C" style="-uslm-lc:I650124"><num class="fontsize10" style="-uslm-lc:emspace2" value="C">(C) </num><content>any successor documents.</content></subparagraph></paragraph></section>
<section id="d1542e165" identifier="/us/bill/118/hr/8663/s4" style="-uslm-lc:I650141"><num class="fontsize12" value="4">SEC. 4. </num><heading>RULE OF CONSTRUCTION.</heading><content style="-uslm-lc:I650120">  Nothing in this Act may be construed to limit the authority of agencies currently managing, overseeing, or otherwise involved in drug equipment and reference libraries.</content></section>
</main>
<signatures>
<signature><role style="-uslm-lc:I650114">Speaker of the House of Representatives.</role></signature>
<signature><role style="-uslm-lc:I650114">Vice President of the United States and  President of the Senate.</role></signature>
</signatures>
</bill>